Skip to content

Study for Tong-Mai Yang-Xin pill for delaying the myocardial reconstruction after PCI operation of coronary heart disease

Clinical study which based on the combination of disease and syndrome to estimating the effects of intervening myocardial remodeling after PCI for coronary heart disease of Tong-Mai Yang-Xin pill

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023023
Enrollment
Unknown
Registered
2019-05-07
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease (CHD)

Interventions

Sponsors

The First Affiliated Hospital of He'nan University of CM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patients with acute anterior myocardial infarction within 10 days, underwent emergency PCI, or underwent PCI after emergency thrombolytic therapy, or received elective PCI within 10 days; 2. The patients meet the syndrome differentiation standard of TCM with Deficient Qi and Yin combined blood stasis; 3. Aged 18 to 75 years, both men and women; 4. Sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. The patients with Multiple coronary artery branches lesions didnt receive elective PCI within 10 days; 2. Acute myocardial infarction with severe complications, such as acute heart failure, cardiogenic shock(conventional treatment cannot correct), or mechanical complication; 3. Acute myocardial infarction with heart failure, Killip classification III or IV; 4. Chronic heart failure or old anterior myocardial infarction in the past medical history; 5. Combined with other diseases, such as cardiomyopathy, rheumatic heart disease, valvular heart disease (Severe stenosis/incomplete closure), arrhythmia (persistent atrial fibrillation/atrial flutter, third degree a-v block, sick sinus syndrome, after implantation of pacemaker) hyperthyroidism, cardiac tamponade, pulmonary arterial hypertensionacute paroxysmal asthma/COPD, severe infection , and so on; 6. Patients with severe liver and kidney function impairment (ALT, AST or TBIL>3 times the upper limit of normal reference value, or Cr >=3mg/dL or eGFR=60ml/min1.73m2); and with severe primary diseases or mental diseases such as hematopoietic system; 7. Patients with malignant tumor; 8. Allergic constitution or allergy to multiple drug or food, allergy to known components of the study drugs; 9. Cannot take care of themselves and cannot receive oral drug; 10. Participated in other drug clinical trials within 1 month; 11. Suspecting or ensuring with a history of substance abuse alcohol or drug abuse; 12. Pregnant or lactating women, or planned pregnancy; 13. According to the judgment of the researcher, the subject is not suitable for involving.

Design outcomes

Primary

MeasureTime frame
left ventricular end-diastolic volume index;

Secondary

MeasureTime frame
Chinese medicine symptom complex score;Echocardiography;six-minute walk test;Seattle angina scale score;cardiac magnetic resonance imagingCMRI;biological indicator;NT-proBNP;Ambulatory ECG;Cardiovascular related deaths;Cardiovascular related hospitalization;Revascularization;

Countries

China

Contacts

Public ContactWang Yongxia

The First Affiliated Hospital of He'nan University of CM

wyxchzhq@163.com+86 13838571596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026